Nanomedicine · 2019 · 19 citations · 20 references
PharmacyNeurosciencePharmacologyDrug DeliveryNanoparticle Drug DeliveryNeuropharmacologyDrug EncapsulationNanocarriers For TherapeuticsNanomaterials For Drug DeliveryNanomedicineNasal Drug DeliveryNasal FormulationsChitosanChitosan NanocarriersNanoparticle Nasal FormulationsNasal AdministrationNasal NanoemulsionsSystemic AdministrationTissue PenetrationTissue Penetration Efficiency
Aim: To determine whether a p38 MAPK inhibitor incorporated into nanoemulsion-based chitosan nanocapsules can reduce the activity of this kinase in the brain through their nasal administration in mice. Materials & methods: We selected the p38 MAPK inhibitor PH797804, an ATP-competitive inhibitor of p38α encapsulated in nanoemulsion-based chitosan nanocapsules. Biological effect was evaluated in microglial and neuronal cells in vitro and in ex vivo and in vivo systems, in a mouse model of Alzheimer’s disease. Results: Encapsulated inhibitor retains enzymatic inhibitory activity and tissue penetration capacity in vitro, ex vivo and in vivo. Conclusion: Nasal administration of chitosan nanocapsules can be an effective approach for brain-restricted reduction of p38 MAPK activity, thus reducing the side effects of systemic administration.
20
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration
Liya Qin, Xuefei Wu, Michelle L. Block et al. · Glia · 2007 · 2.2K citations · Full text
Single App knock-in mouse models of Alzheimer's disease
Takashi Saito, Yukio Matsuba, Naomi Mihira et al. · Nature Neuroscience · 2014 · 1.4K citations
Immortalization of murine microglial cells by a v-raf / v-myc carrying retrovirus
Elisabetta Blasi, R. Barluzzi, V. Bocchini et al. · Journal of Neuroimmunology · 1990 · 1.1K citations · Full text
Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles
Ejaj Ahmad, Yunhai Feng, Jianping Qi et al. · Nanoscale · 2016 · 188 citations